This week in Drug Discovery (1 – 5 December)
News round-up for 1 – 5 December by Bruno Quinney, Content Team at DDW.
This week in DDW, a trade agreement between the UK and the US promises to support the life sciences industry and secure access to drugs. Elsewhere, novel therapies could break new ground in treating neurodegenerative diseases.
The top stories:
UK-US pharmaceuticals deal supports UK life sciences
A trade deal has been agreed between the UK and the US, which the governments say will secure and expand access to drugs, safeguard the medicines supply chain, and “drive crucial investment while supporting UK patients and industries”.
Read more…
Decline in trial recruitment denying patients, ABPI warns
The decline in commercial clinical trial recruitment is denying patients participation in cutting-edge research, the Association of the British Pharmaceutical Industry (ABPI) has warned.
Novel therapeutic could treat neurodegenerative diseases
A novel therapeutic could improve memory, cognitive function and neuroinflammation in neurodegenerative diseases.
Custom-designed peptide could treat Alzheimer’s
SOBIN-AD, developed by biotechnology company AltPep Corporation, demonstrated potential to improve cognition both before and after the onset of cognitive impairment in pre-clinical trial.
Read more…
$30,000 award up for grabs in metabolomics research
Biotechnology company NADMED has launched an award worth $30,000 to accelerate breakthroughs in metabolomics research.
